Studies eslicarbazepine in adults with focal-onset seizures
Observes eslicarbazepine in adults with focal-onset seizures during routine care.
Plain-language title generated from the registry record
Registry title: Prospective Study of Eslicarbazepine in Adults With Focal-Onset Seizures
Key facts
- Where
- Lahore, PakistanSee the site
Where in Pakistan
- Mayo Hospital LahoreLahore, PakistanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- King Edward Medical University
- Trial code
- NCT07793396
- Record updated
- 9 September 2026
- Original description
This prospective multicenter observational study will evaluate the effectiveness, safety, tolerability, and impact on quality of life of eslicarbazepine in adults with focal-onset seizures in routine clinical practice. Participants will include newly diagnosed patients and patients previously treated with carbamazepine or oxcarbazepine who have inadequate seizure control or intolerable adverse effects. Treatment with eslicarbazepine will be initiated or changed at the discretion of the treating physician in accordance with routine clinical practice. Participants will be followed for 3 months.Read full original descriptionShow less
A Prospective, Real-World Evidence, Multicenter Study to Evaluate the Efficacy and Safety of Eslicarbazepine in Managing Epilepsy
This prospective multicenter observational study will evaluate the effectiveness, safety, tolerability, and impact on quality of life of eslicarbazepine in adults with focal-onset seizures in routine clinical practice. Participants will include newly diagnosed patients and patients previously treated with carbamazepine or oxcarbazepine who have inadequate seizure control or intolerable adverse effects. Treatment with eslicarbazepine will be initiated or changed at the discretion of the treating physician in accordance with routine clinical practice. Participants will be followed for 3 months.
Inclusion: Adult patients (aged at least 18 years) with diagnosed partial-onset seizures; Newly diagnosed (treatment-naïve) or previously treated with Carbamazepine or Oxcarbazepine and inadequately controlled or intolerant; Patient or Legal Representative is willing and able to provide informed consent, or, in the absence of a legal representative, an Independent Healthcare Professional provides authorization for patient enrolment.
Exclusion: Patients who have a contraindication to the medicine or any component of prescribed therapy; Any hypersensitivity to Eslicarbazepine; Female patients who are pregnant or lactating.